3-(2'-pyridyldithio)benzyldiazoacetate has been researched along with olaparib in 1 studies
| Studies (3-(2'-pyridyldithio)benzyldiazoacetate) | Trials (3-(2'-pyridyldithio)benzyldiazoacetate) | Recent Studies (post-2010) (3-(2'-pyridyldithio)benzyldiazoacetate) | Studies (olaparib) | Trials (olaparib) | Recent Studies (post-2010) (olaparib) |
|---|---|---|---|---|---|
| 34 | 0 | 33 | 1,313 | 172 | 1,258 |
| Protein | Taxonomy | 3-(2'-pyridyldithio)benzyldiazoacetate (IC50) | olaparib (IC50) |
|---|---|---|---|
| Poly [ADP-ribose] polymerase tankyrase-1 | Homo sapiens (human) | 1.538 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 0.02 | |
| Cholinesterase | Homo sapiens (human) | 0.0035 | |
| Poly [ADP-ribose] polymerase 1 | Homo sapiens (human) | 0.1741 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.02 | |
| Protein mono-ADP-ribosyltransferase PARP6 | Homo sapiens (human) | 1.8 | |
| Protein mono-ADP-ribosyltransferase PARP15 | Homo sapiens (human) | 7.6216 | |
| Protein mono-ADP-ribosyltransferase PARP10 | Homo sapiens (human) | 5.2854 | |
| Protein mono-ADP-ribosyltransferase PARP16 | Homo sapiens (human) | 5.1143 | |
| Poly [ADP-ribose] polymerase tankyrase-2 | Homo sapiens (human) | 2.3349 | |
| Histamine H3 receptor | Cavia porcellus (domestic guinea pig) | 0.001 | |
| Poly [ADP-ribose] polymerase 2 | Homo sapiens (human) | 0.1866 | |
| Protein mono-ADP-ribosyltransferase PARP4 | Homo sapiens (human) | 0.4087 | |
| Protein mono-ADP-ribosyltransferase PARP3 | Homo sapiens (human) | 0.1315 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, G; Fan, J; Fu, Y; Guo, E; Hu, D; Hu, X; Li, Z; Liu, C; Lu, F; Qin, T; Qin, X; Sun, C; Wang, W; Xiao, R; Xiong, Y; Yang, B; Zhang, L | 1 |
1 other study(ies) available for 3-(2'-pyridyldithio)benzyldiazoacetate and olaparib
| Article | Year |
|---|---|
Codelivery of adavosertib and olaparib by tumor-targeting nanoparticles for augmented efficacy and reduced toxicity.
Topics: Animals; Cell Line, Tumor; Female; Humans; Mice; Nanoparticle Drug Delivery System; Nanoparticles; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Tumor Microenvironment | 2023 |